Advertisement

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy

Published:February 05, 2016DOI:https://doi.org/10.1016/j.clinimag.2016.02.005

      Abstract

      Objectives

      To determine transrectal ultrasound (TRUS) visibility of magnetic resonance (MR) lesions.

      Methods

      Data from 34 patients with 56 MR lesions and prostatectomy were used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to Prostate Imaging–Reporting and Data System (PIRADS) and Gleason scores.

      Results

      TRUS visibility occurred in 43% of all MR lesions and in 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS-visible lesions had a Gleason 4 or 5 component.

      Conclusions

      Almost half of the MR lesions were visible on TRUS. TRUS-visible lesions were more aggressive than TRUS-invisible lesions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heijmink SWTPJ
        • van Moerkerk H
        • Kiemeney LALM
        • Witjes JA
        • Frauscher F
        • Barentsz JO
        A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.
        Eur Radiol. 2006; 16 ([Available from: http://dx.doi.org/10.1007/s00330-005-0035-y]): 927-938
        • Norberg M
        • Egevad L
        • Holmberg L
        • Sparén P
        • Norlén BJ
        • Busch C
        The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer.
        Urology. 1997; 50 ([Available from: http://dx.doi.org/10.1016/S0090-4295(97)00306–3]): 562-566
        • Terris MK
        Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: preliminary report.
        Urology. 1999; 54: 486-489
        • Fütterer JJ
        • Heijmink SWTPJ
        • Scheenen TWJ
        • Veltman J
        • Huisman HJ
        • Vos P
        • et al.
        Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.
        Radiology. 2006; 241 ([Available from: http://dx.doi.org/10.1148/radiol.2412051866]): 449-458
        • Kitajima K
        • Kaji Y
        • Fukabori Y
        • Yoshida K
        • Suganuma N
        • Sugimura K
        Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging.
        J Magn Reson Imaging. 2010; 31 ([Available from: http://dx.doi.org/10.1002/jmri.22075]): 625-631
        • Tanimoto A
        • Nakashima J
        • Kohno H
        • Shinmoto H
        • Kuribayashi S
        Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
        J Magn Reson Imaging. 2007; 25 (Available from: http://dx.doi.org/10.1002/jmri.20793): 146-152
        • Barentsz JO
        • Richenberg J
        • Clements R
        • Choyke P
        • Verma S
        • Villeirs G
        • et al.
        ESUR Prostate MR Guidelines 2012.
        Eur Radiol. 2012; 22: 746-757
        • Roethke MC
        • Kuru TH
        • Schultze S
        • Tichy D
        • Kopp-Schneider A
        • Fenchel M
        • et al.
        Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
        Eur Radiol. 2014; 24 ([Available from: http://dx.doi.org/10.1007/s00330-013-3017-5]): 344-352
        • Rosenkrantz AB
        • Kim S
        • Lim RP
        • Hindman N
        • Deng FM
        • Babb JS
        • et al.
        Prostate cancer localization using multiparametric MR imaging: comparison of prostate imaging reporting and data system (PI-RADS) and Likert scales.
        Radiology. 2013; 269 ([Available from: http://dx.doi.org/10.1148/radiol.13122233]): 482-492
        • Moore CM
        • Robertson NL
        • Arsanious N
        • Middleton T
        • Villers A
        • Klotz L
        • et al.
        Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
        Eur Urol. 2013; 63 ([Available from: http://dx.doi.org/10.1016/j.eururo.2012.06.004]): 125-140
        • Hambrock T
        • Somford DM
        • Hoeks C
        • Bouwense SAW
        • Huisman H
        • Yakar D
        • et al.
        Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
        J Urol. 2010; 183 ([Available from: http://dx.doi.org/10.1016/j.juro.2009.10.022]): 520-527
        • Hambrock T
        • Hoeks C
        • Hulsbergen-van de Kaa C
        • Scheenen T
        • Fütterer J
        • Bouwense S
        • et al.
        Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.
        Eur Urol. 2012; 61 ([Available from: http://dx.doi.org/10.1016/j.eururo.2011.08.042]): 177-184
        • Cornud F
        • Brolis L
        • Delongchamps NB
        • Portalez D
        • Malavaud B
        • Renard-Penna R
        • et al.
        TRUS-MRI image registration: a paradigm shift in the diagnosis of significant prostate cancer.
        Abdom Imaging. 2013; 38 ([Available from: http://dx.doi.org/10.1007/s00261-013-0018-4]): 1447-1463
        • Delongchamps NB
        • Peyromaure M
        • Schull A
        • Beuvon F
        • Bouazza N
        • Flam T
        • et al.
        Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies.
        J Urol. 2013; 189 ([Available from: http://dx.doi.org/10.1016/j.juro.2012.08.195]): 493-499
        • Hadaschik BA
        • Kuru TH
        • Tulea C
        • Rieker P
        • Popeneciu IV
        • Simpfendörfer T
        • et al.
        A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion.
        J Urol. 2011; 186 ([Available from: http://dx.doi.org/10.1016/j.juro.2011.07.102]): 2214-2220
        • Miyagawa T
        • Ishikawa S
        • Kimura T
        • Suetomi T
        • Tsutsumi M
        • Irie T
        • et al.
        Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data.
        Int J Urol. 2010; 17 ([Available from: http://dx.doi.org/10.1111/j.1442-2042.2010.02612.x]): 855-860
        • Puech P
        • Rouvière O
        • Renard-Penna R
        • Villers A
        • Devos P
        • Colombel M
        • et al.
        Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy—prospective multicenter study.
        Radiology. 2013; 268 ([Available from: http://dx.doi.org/10.1148/radiol.13121501]): 461-469
        • Siddiqui MM
        • Rais-Bahrami S
        • Truong H
        • Stamatakis L
        • Vourganti S
        • Nix J
        • et al.
        Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
        Eur Urol. 2013; 64 ([Available from: http://dx.doi.org/10.1016/j.eururo.2013.05.059]): 713-719
        • Sonn GA
        • Chang E
        • Natarajan S
        • Margolis DJ
        • Macairan M
        • Lieu P
        • et al.
        Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
        Eur Urol. 2013; 65 ([Available from: http://dx.doi.org/10.1016/j.eururo.2013.03.025]): 809-815
        • Walton Diaz A
        • Hoang AN
        • Turkbey B
        • Hong CW
        • Truong H
        • Sterling T
        • et al.
        Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates?.
        J Urol. 2013; 190: 2020-2025
        • Mozer P
        • Rouprêt M
        • Le Cossec C
        • Granger B
        • Comperat E
        • de Gorski A
        • et al.
        First round of targeted biopsies with magnetic resonance imaging/ultrasound-fusion images compared to conventional ultrasound-guided trans-rectal biopsies for the diagnosis of localised prostate cancer.
        Br J Urol Int. 2015; 115 ([Available from: http://dx.doi.org/10.1111/bju.12690]): 50-57
        • Delongchamps NB
        • Lefèvre A
        • Bouazza N
        • Beuvon F
        • Legman P
        • Cornud F
        Detection of significant prostate cancer with magnetic resonance targeted biopsies—should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?.
        J Urol. 2015; 193: 1198-1204
        • Ukimura O
        • Marien A
        • Palmer S
        • Villers A
        • Aron M
        • de Castro Abreu AL
        • et al.
        Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.
        World J Urol. 2015; ([Available from: http://dx.doi.org/10.1007/s00345-015-1501-z])
        • Weinreb JC
        • Barentsz JO
        • Choyke PL
        • Curnud F
        • Haider MA
        • Macura KJ
        • et al.
        PI-RADS PIRADS imaging—reporting and data system: 2015, version 2.
        Eur Urol. 2016; 69: 16-40
        • Barentsz JO
        • Weinreb JC
        • Verma S
        • Thoeny HC
        • Tempany CM
        • Shtern F
        • et al.
        Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use.
        Eur Urol. 2016; 69: 41-49
        • Epstein JI
        • Allsbrook WC
        • Amin MB
        • Egevad LL
        ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma.
        Am J Surg Pathol. 2005; 29: 1228-1242
        • Fleshner NE
        • O'Sullivan M
        • Premdass C
        • Fair WR
        Clinical significance of small (less than 0.2 cm3) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels less than 10 ng/mL.
        Urology. 1999; 53: 356-358
        • Onur R
        • Littrup PJ
        • Pontes JE
        • Bianco FJ
        Contemporary impact of transrectal ultrasound lesions for prostate cancer detection.
        J Urol. 2004; 172 ([Available from: http://dx.doi.org/10.1097/01.ju.0000131621.61732.6b]): 512-514
        • Spajic B
        • Eupic H
        • Tomas D
        • Stimac G
        • Kruslin B
        • Kraus O
        The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens.
        Urology. 2007; 70 ([Available from: http://dx.doi.org/10.1016/j.urology.2007.06.1092]): 734-737
        • Sperandeo G
        • Sperandeo M
        • Morcaldi M
        • Caturelli E
        • Dimitri L
        • Camagna A
        Transrectal ultrasonography for the early diagnosis of adenocarcinoma of the prostate: a new maneuver designed to improve the differentiation of malignant and benign lesions.
        J Urol. 2003; 169 ([Available from: http://dx.doi.org/10.1097/01.ju.0000045640.71845.b8]): 607-610
        • van de Ven WJM
        • Hulsbergen-van de Kaa CA
        • Hambrock T
        • Barentsz JO
        • Huisman HJ
        Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies.
        Eur Radiol. 2013; 23 ([Available from: http://dx.doi.org/10.1007/s00330-012-2701-1]): 1401-1407